Rondoni John 4
4 · Inspire Medical Systems, Inc. · Filed Nov 5, 2024
Insider Transaction Report
Form 4
Rondoni John
See Remarks
Transactions
- Sale
Common Stock
2024-11-01$193.92/sh−1,580$306,394→ 12,694 total - Sale
Common Stock
2024-11-01$194.84/sh−1,013$197,373→ 11,681 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2024-11-01−5,802→ 1,448 totalExercise: $71.00Exp: 2029-12-16→ Common Stock (5,802 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2024-11-01−2,901→ 9,197 totalExercise: $42.15Exp: 2029-12-18→ Common Stock (2,901 underlying) - Sale
Common Stock
2024-11-01$196.42/sh−333$65,408→ 11,348 total - Sale
Common Stock
2024-11-01$192.93/sh−5,777$1,114,557→ 14,274 total - Exercise/Conversion
Common Stock
2024-11-01$71.00/sh+5,802$411,942→ 17,150 total - Exercise/Conversion
Common Stock
2024-11-01$42.15/sh+2,901$122,277→ 20,051 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.35 to $193.34. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.38 to $194.375. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.50 to $195.28. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.22 to $196.715. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The option is fully vested and exercisable.